TVTX
Travere Therapeutics, Inc.
+1.04 (+1.64%)64.52USD302K成交股數6.1B市值–本益比(近四季)10.3股價營收比+48.2%營收年增(近四季)2026-10-29下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 170M+48% | 127M+56% | 130M+106% | 165M+205% | 114M+177% | 81.7M+81% | 62.9M+70% | 54.1M+68% | 41.4M | 45.1M | 37.1M | 32.2M |
| 營業成本 | 2.2M | 2.0M | 2.6M | 1.6M | 1.5M | 4.7M | 1.6M | 2.1M | 1.5M | – | 1.3M | 1.5M |
| 毛利 | 167M+48% | 125M+63% | 127M+107% | 163M+214% | 113M+183% | 77.1M | 61.3M+71% | 52.1M+69% | 39.9M | – | 35.8M | 30.7M |
| 毛利率 | 98.7% | 98.5% | 98.0% | 99.0% | 98.7% | 94.3% | 97.4% | 96.2% | 96.4% | – | 96.5% | 95.5% |
| 研發費用 | 60.3M | 57.1M | 57.9M | 51.9M | 49.4M | 46.9M | 51.7M | 54.3M | 49.4M | – | 60.6M | 66.5M |
| 銷售管理費用 | 96.1M | 80.3M | 128M | 86.5M | 62.6M | 60.4M | 65.6M | 64.8M | 64.2M | – | 67.8M | 68.2M |
| 營業利益 | 4.0M-131% | −36.9M-13% | −32.4M-42% | 24.9M-137% | −12.7M-91% | −42.7M-55% | −56.1M-39% | −67.7M-35% | −139M | −94.2M | −92.6M | −104M |
| 營業利益率 | 2.3% | -29.0% | -25.0% | 15.1% | -11.1% | -52.2% | -89.3% | -125.1% | -336.5% | -209.1% | -249.6% | -322.9% |
| 稅後淨利 | −34.8M+173% | −37.1M-10% | 2.7M-105% | 25.7M-137% | −12.8M-91% | −41.2M-54% | −54.8M-136% | −70.4M-18% | −136M | −90.2M | 151M | −85.6M |
| 淨利率 | -20.5% | -29.2% | 2.1% | 15.6% | -11.1% | -50.4% | -87.1% | -130.1% | -328.9% | -200.1% | 406.3% | -266.0% |
| 稀釋 EPS | -0.37+164% | -0.40-15% | 0.04-106% | 0.28-131% | -0.14-92% | -0.47-60% | -0.70-136% | -0.91-19% | -1.76 | -1.18 | 1.97 | -1.13 |
| 稀釋股數 | 93.5M | 91.9M | 89.2M | 103M | 88.9M | 88.4M | 77.8M | 77.5M | 77.1M | – | 76.3M | 76.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 118M | 78.4M | 93.0M | 111M | 75.2M | 61.9M | 36.4M | 32.3M | 43.3M | 58.2M | 144M | 70.9M |
| 應收帳款 | 80.6M | 87.3M | 80.1M | 83.0M | 38.7M | 34.4M | 25.2M | 24.5M | 22.7M | 21.2M | 14.6M | 20.4M |
| 存貨 | 40.0M | 37.1M | 36.2M | 37.5M | 37.7M | 38.0M | 42.9M | 43.0M | 42.3M | 9.4M | 20.8M | 18.8M |
| 總資產 | 799M | 555M | 605M | 539M | 555M | 549M | 504M | 551M | 664M | 789M | 833M | 736M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 775M | 456M | 490M | 465M | 523M | 516M | 535M | 536M | 589M | 588M | 553M | 620M |
| 股東權益 | 24.5M | 98.7M | 115M | 73.6M | 32.7M | 32.8M | −30.5M | 15.1M | 74.1M | 201M | 280M | 116M |
| 負債比 | 96.9% | 82.2% | 81.0% | 86.3% | 94.1% | 94.0% | 106.0% | 97.3% | 88.8% | 74.5% | 66.4% | 84.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −40.4M-4% | – | – | – | −42.2M | – | – | −119M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | 0.00 | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | −119M | – | – | – |
| 折舊攤銷 | – | 25.2M | – | – | – | 12.8M | – | – | 9.9M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -287.6% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 491M
| Reportable | 491M | 100.0% | +110.5% |
|---|
產品／服務2025 年度 · 491M
| FILSPARI | 322M | 65.6% | +143.5% |
|---|---|---|---|
| Tiopronin Products | 88.5M | 18.0% | -6.4% |
| License | 80.3M | 16.4% | +1141.0% |
| 產品 小計 | 410M | 83.6% | +81.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 491M | +110.5% | −25.5M | -5.2% | -0.29 | – |
| FY2024 | 233M | +60.5% | −322M | -137.9% | -4.08 | – |
| FY2023 | 145M | +32.7% | −111M | -76.7% | -1.50 | −281M |
| FY2022 | 109M | -17.0% | −278M | -254.4% | -4.37 | −186M |
| FY2021 | 132M | -33.5% | −180M | -136.6% | -3.01 | −19.9M |
| FY2020 | 198M | +13.1% | −169M | -85.4% | -3.56 | −49.5M |
| FY2019 | 175M | +6.8% | −146M | -83.5% | -3.46 | −58.4M |
| FY2018 | 164M | – | −103M | -62.5% | -2.54 | −25.7M |